Skip to main content
. Author manuscript; available in PMC: 2014 Nov 15.
Published in final edited form as: Biol Psychiatry. 2013 Jun 14;74(10):10.1016/j.biopsych.2013.04.025. doi: 10.1016/j.biopsych.2013.04.025

Figure 4. Behavioral actions of scopolamine in the FST require mTORC1 signaling and glutamate-AMPA receptors.

Figure 4

Rats were administered scopolamine or telenzapine at the doses indicated and immobility in the FST was determined 24 hr later. (a) Both scopolamine and telenzapine significantly decreased immobility in the FST at the same doses that increased mTORC1 signaling and synaptogenesis. Values represent mean ± SEM (n = 3 per group (Sco) and n=6 per group (Tel); *P < 0.05 compared to control. (b) Pretreatment with the selective mTORC1 inhibitor rapamycin (0.2 nmol, i.c.v., 30 min before scopolamine) completely blocked the antidepressant effects of scopolamine (25 µg/kg, i.p.). Values represent mean ± SEM (n = 7 per group; *P < 0.05 compared to scopolamine alone (ANOVA). (c) Pretreatment with the selective AMPA receptor antagonist NBQX (10 mg/kg, i.p. 30 min before scopolamine) completely blocked the antidepressant effects of scopolamine (25 µg/kg, i.p.). Values represent mean ± SEM (n = 9; *P < 0.05 compared to control by ANOVA.